Intercept Pharmaceuticals Inc (NASDAQ:ICPT) saw a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 4,910,000 shares, an increase of 8.1% from the January 15th total of 4,540,000 shares. Approximately 19.5% of the shares of the company are short sold. Based on an average daily trading volume, of 684,600 shares, the short-interest ratio is currently 7.2 days.

Several research analysts have commented on ICPT shares. B. Riley lifted their price target on Intercept Pharmaceuticals from $133.00 to $158.00 and gave the stock a “buy” rating in a research report on Thursday, January 9th. Raymond James dropped their price target on Intercept Pharmaceuticals from $148.00 to $147.00 and set a “strong-buy” rating on the stock in a research report on Monday, October 21st. Credit Suisse Group reaffirmed an “outperform” rating and issued a $141.00 price target (up from $87.00) on shares of Intercept Pharmaceuticals in a research report on Tuesday, December 17th. Stifel Nicolaus boosted their price objective on Intercept Pharmaceuticals from $86.00 to $102.00 in a research report on Monday, November 25th. Finally, Canaccord Genuity assumed coverage on Intercept Pharmaceuticals in a research report on Monday, December 2nd. They set a “buy” rating on the stock. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $141.65.

Shares of ICPT traded up $0.15 on Friday, reaching $94.84. 281,086 shares of the stock traded hands, compared to its average volume of 559,655. The firm has a market cap of $3.10 billion, a price-to-earnings ratio of -8.72 and a beta of 1.74. The company has a debt-to-equity ratio of 4.02, a current ratio of 5.49 and a quick ratio of 5.49. Intercept Pharmaceuticals has a 12 month low of $56.76 and a 12 month high of $131.87. The stock’s 50-day moving average price is $105.52 and its 200-day moving average price is $85.09.

In other Intercept Pharmaceuticals news, General Counsel Ryan T. Sullivan sold 12,154 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $85.00, for a total value of $1,033,090.00. Following the transaction, the general counsel now directly owns 34,043 shares of the company’s stock, valued at approximately $2,893,655. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Christian Weyer sold 1,550 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $85.00, for a total value of $131,750.00. Following the completion of the transaction, the executive vice president now directly owns 15,759 shares in the company, valued at $1,339,515. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 57,434 shares of company stock worth $5,599,019. Company insiders own 5.00% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Invesco Ltd. lifted its holdings in Intercept Pharmaceuticals by 27.7% in the 2nd quarter. Invesco Ltd. now owns 12,790 shares of the biopharmaceutical company’s stock valued at $1,018,000 after purchasing an additional 2,773 shares in the last quarter. Peregrine Capital Management LLC increased its stake in shares of Intercept Pharmaceuticals by 29.8% during the 3rd quarter. Peregrine Capital Management LLC now owns 167,902 shares of the biopharmaceutical company’s stock valued at $11,142,000 after acquiring an additional 38,556 shares during the last quarter. Wedbush Securities Inc. increased its stake in shares of Intercept Pharmaceuticals by 13.7% during the 3rd quarter. Wedbush Securities Inc. now owns 7,936 shares of the biopharmaceutical company’s stock valued at $527,000 after acquiring an additional 957 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Intercept Pharmaceuticals by 43.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,768 shares of the biopharmaceutical company’s stock valued at $117,000 after acquiring an additional 539 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D acquired a new position in shares of Intercept Pharmaceuticals during the 3rd quarter valued at about $2,190,000. 79.14% of the stock is currently owned by institutional investors and hedge funds.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

Featured Article: Balance Sheet

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.